Judge Denied Motion to Dismiss Revlimid Antitrust Claims
A federal judge ruled that antitrust litigation against Celgene, Teva, and AbbVie regarding Revlimid can proceed.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Should the government take stronger action against pharmaceutical companies that allegedly block generic competition?
District Judge Michael E. Farbiarz denied a motion to dismiss antitrust claims alleging a conspiracy to illegally monopolize the market for the drug Revlimid. The ruling enables the legal case to move forward against Celgene, Teva, and AbbVie.
Why it matters
The court identified a plausible pay-for-delay agreement between Celgene and Natco that allegedly limited competition. This legal development addresses concerns regarding potential market manipulation and the accessibility of generic pharmaceutical alternatives.
The litigation targets three pharmaceutical companies for an alleged conspiracy to monopolize the Revlimid market. The case centers on claims that a settlement agreement allowed for high per-unit pricing on generic versions of the drug.
The players
Michael E. Farbiarz
Michael E. Farbiarz is a United States District Judge presiding over the antitrust litigation involving the drug Revlimid.
Celgene
Celgene is a biopharmaceutical company involved in the development and marketing of the drug Revlimid.
Teva
Teva is a pharmaceutical company named as a defendant in the antitrust claims regarding market competition for Revlimid.
AbbVie
AbbVie is a major biopharmaceutical company named as a defendant in the current legal action over Revlimid monopoly allegations.
Natco
Natco is a pharmaceutical company accused of entering a pay-for-delay settlement agreement with Celgene.
The details
The lawsuit claims that a settlement agreement effectively split the market between Celgene and Natco, which allegedly allowed Natco to maintain high pricing for generic Revlimid by mirroring Celgene's established cost structure. The judge's decision ensures that these allegations of anticompetitive behavior will be subject to further judicial review.
Timeline
September 29, 2026: The district judge officially denied the motion to dismiss the antitrust claims.
Market Landscape
The ruling signals a continued judicial focus on pharmaceutical industry competition under the Sherman Antitrust Act. By allowing the suit to proceed, the court is addressing broader concerns about how settlement agreements may be used to suppress market competition.
The continuation of this lawsuit may eventually impact the availability and cost of generic versions of Revlimid for patients. Consumers should monitor the case as it progresses, as outcomes could lead to changes in pharmaceutical pricing structures.
The takeaway
This ruling highlights the high level of scrutiny currently applied to pharmaceutical settlement agreements and their impact on generic drug markets. Stakeholders should recognize that federal courts are increasingly willing to hear arguments regarding the anticompetitive effects of pay-for-delay deals.
Further reading
For more on how legal actions are shaping the industry, visit the United States Healthcare section.
Source note: This article includes information reported by Mlex.
Live Poll
Should the government take stronger action against pharmaceutical companies that allegedly block generic competition?
